Loading
A phase 1/2 trial of ABT-301, Tislelizumab, Bevacizumab in colorectal cancer, run by Anbogen Therapeutics, Inc., now recruiting.
A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC is a phase 1/2 interventional study registered as NCT07244705 by Anbogen Therapeutics, Inc., with 66 participants planned, started 2025-11 and due to reach its primary completion in 2028-04. Interventions recorded: ABT-301, Tislelizumab, Bevacizumab (Avastin). Conditions listed: Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic, Colorectal Cancer (CRC), Immunotherapy. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Tislelizumab, Bevacizumab, Anti-angiogenic therapy, Monoclonal antibodies.
Shares Tislelizumab, Colorectal cancer, Immune checkpoint inhibitors.
Shares Tislelizumab, Colorectal cancer, Immune checkpoint inhibitors.
Shares Tislelizumab, Bevacizumab, Immune checkpoint inhibitors.
Shares Tislelizumab, Anti-angiogenic therapy, Immune checkpoint inhibitors.
Shares Tislelizumab, Anti-angiogenic therapy, Immune checkpoint inhibitors.
Shares Tislelizumab, Anti-angiogenic therapy, Immune checkpoint inhibitors.
Shares Tislelizumab, Anti-angiogenic therapy, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/